Filing Details

Accession Number:
0001415889-23-011882
Form Type:
4
Zero Holdings:
No
Publication Time:
2023-08-04 19:33:10
Reporting Period:
2023-08-02
Accepted Time:
2023-08-04 19:33:10
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
855654 Immunogen Inc. IMGN Pharmaceutical Preparations (2834) 042726691
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1814150 Ann Stacy Coen C/O Immunogen, Inc.
830 Winter Street
Waltham MA 02451
Svp & Chief Business Officer No No No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2023-08-02 4,255 $4.92 15,215 No 4 M Direct
Common Stock Disposition 2023-08-02 4,255 $18.12 10,960 No 4 S Direct
Common Stock Acquisiton 2023-08-04 80,326 $4.92 91,286 No 4 M Direct
Common Stock Disposition 2023-08-04 80,326 $17.05 10,960 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 M Direct
No 4 S Direct
No 4 M Direct
No 4 S Direct
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Common Stock Stock Option (Right to Buy) Disposition 2023-08-02 4,255 $0.00 4,255 $4.92
Common Stock Stock Option (Right to Buy) Disposition 2023-08-04 80,326 $0.00 80,326 $4.92
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
255,745 2021-06-01 2030-06-01 No 4 M Direct
175,419 2021-06-01 2030-06-01 No 4 M Direct
Footnotes
  1. The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $18.01 to $18.15, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within these ranges.
  2. The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $17.00 to $17.12, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within these ranges.
  3. Exercisable as to 25% on the first year anniversary of the grant and 6.25% quarterly for the subsequent three years.